NCT00389090View on ClinicalTrials.gov

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

February 28, 2009

Conditions
GliomaAstrocytomaOligodendrogliomaOligoastrocytoma
Interventions
DRUG

Temozolomide and O6-Benzylguanine

O6BG + Temozolomide

Trial Locations (12)

27710

AOI Pharmaceuticals Investigative Site, Durham

29605

AOI Pharmaceuticals Investigative Site, Greenville

32804

AOI Pharmaceuticals Investigative Site, Orlando

40202

AOI Pharmaceuticals Investigative Site, Louisville

40536

AOI Pharmaceuticals Investigative Site, Lexington

54407

AOI Pharmaceuticals Investigative Site, Minneapolis

60201

AOI Pharmaceuticals Investigative Site, Evanston

60611

AOI Pharmaceuticals Investigative Site, Chicago

75246

AOI Pharmaceuticals Investigative Site, Dallas

77024

AOI Pharmaceuticals Investigative Site, Houston

84132

AOI Pharmaceuticals Investigative Site, Salt Lake City

90033

AOI Pharmaceuticals Investigative Site, Los Angeles

Sponsors
All Listed Sponsors
lead

Keryx / AOI Pharmaceuticals, Inc.

INDUSTRY

NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | Biotech Hunter | Biotech Hunter